Abstract
A detailed pathological description of the muscle findings in a case of the neuroleptic malignant syndrome (NMS) following ingestion of lysergic acid diethylamide (LSD) is given, including the first ultrastructural analysis. Focal necrosis, oedema, and hypercontraction of fibres with glycogen and lipid depletion, were identified, all of which had resolved completely a year later. The findings are compared with those in malignant hyperthermia. It is suggested that the results support the view that in NMS, the muscle rigidity is due to central mechanisms and, in both this disorder and malignant hyperthermia, it is responsible for the hyperpyrexia and its life-threatening complications.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Caroff S. N., Rosenberg H., Fletcher J. E., Heiman-Patterson T. D., Mann S. C. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology. 1987 Jul;67(1):20–25. doi: 10.1097/00000542-198707000-00004. [DOI] [PubMed] [Google Scholar]
- Ellis K. O., Castellion A. W., Honkomp L. J., Wessels F. L., Carpenter J. E., Halliday R. P. Dantrolene, a direct acting skeletal muscle relaxant. J Pharm Sci. 1973 Jun;62(6):948–951. doi: 10.1002/jps.2600620619. [DOI] [PubMed] [Google Scholar]
- Gibb W. R., Lees A. J. The neuroleptic malignant syndrome--a review. Q J Med. 1985 Aug;56(220):421–429. [PubMed] [Google Scholar]
- Goulon M., de Rohan-Chabot P., Elkharrat D., Gajdos P., Bismuth C., Conso F. Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases. Neurology. 1983 Apr;33(4):516–518. [PubMed] [Google Scholar]
- Gronert G. A. Malignant hyperthermia. Anesthesiology. 1980 Nov;53(5):395–423. doi: 10.1097/00000542-198011000-00007. [DOI] [PubMed] [Google Scholar]
- Guzé B. H., Baxter L. R., Jr Current concepts. Neuroleptic malignant syndrome. N Engl J Med. 1985 Jul 18;313(3):163–166. doi: 10.1056/NEJM198507183130306. [DOI] [PubMed] [Google Scholar]
- Harriman D. G. Malignant hyperthermia myopathy--a critical review. Br J Anaesth. 1988 Feb;60(3):309–316. doi: 10.1093/bja/60.3.309. [DOI] [PubMed] [Google Scholar]
- Hayward R. A., Shapiro M. F., Oye R. K. Laboratory testing on cerebrospinal fluid. A reappraisal. Lancet. 1987 Jan 3;1(8523):1–4. doi: 10.1016/s0140-6736(87)90698-2. [DOI] [PubMed] [Google Scholar]
- Horn E., Lach B., Lapierre Y., Hrdina P. Hypothalamic pathology in the neuroleptic malignant syndrome. Am J Psychiatry. 1988 May;145(5):617–620. doi: 10.1176/ajp.145.5.617. [DOI] [PubMed] [Google Scholar]
- Martin D. T., Swash M. Muscle pathology in the neuroleptic malignant syndrome. J Neurol. 1987 Dec;235(2):120–121. doi: 10.1007/BF00718024. [DOI] [PubMed] [Google Scholar]
- Mueller P. S., Vester J. W., Fermaglich J. Neuroleptic malignant syndrome. Successful treatment with bromocriptine. JAMA. 1983 Jan 21;249(3):386–388. [PubMed] [Google Scholar]
- Schiller H. H., Mair W. G. Ultrastructural changes of muscle in malignant hyperthermia. J Neurol Sci. 1974 Jan;21(1):93–100. doi: 10.1016/0022-510x(74)90109-9. [DOI] [PubMed] [Google Scholar]
- Somers C. J., McLoughlin J. V. Malignant hyperthermia in pigs: calcium ion uptake by mitochondria from skeletal muscle of susceptible animals given neuroleptic drugs and halothane. J Comp Pathol. 1982 Apr;92(2):191–198. doi: 10.1016/0021-9975(82)90077-9. [DOI] [PubMed] [Google Scholar]
- Tollefson G. D., Garvey M. J. The neuroleptic syndrome and central dopamine metabolites. J Clin Psychopharmacol. 1984 Jun;4(3):150–153. [PubMed] [Google Scholar]